Stock Events

Stock Events

Lidds AB 

0
0
+SEK0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops similar oncology drugs and therapies, competing in the pharmaceuticals market.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a major player in the development and manufacturing of drugs, including cancer treatments that compete with Lidds AB's offerings.
Novartis
NVS
Mkt Cap292.35B
Novartis AG focuses on innovative medicines including oncology, directly competing with Lidds AB's cancer treatment technologies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company specializes in biopharmaceuticals, including cancer drugs that rival Lidds AB's products.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company produces pharmaceutical products, including cancer therapies that compete in the same market as Lidds AB.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC engages in the development of various therapeutic areas, including oncology, competing with Lidds AB's cancer-focused treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major healthcare company that develops cancer treatments, which are in direct competition with Lidds AB's products.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. focuses on human therapeutics, including oncology, which competes with Lidds AB's cancer treatment solutions.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. develops and markets drugs for life-threatening diseases including cancer, competing with Lidds AB.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in biopharmaceutical development, including oncology drugs that compete with Lidds AB's portfolio.

About

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.
Show more...
CEO
Mats Wiking
Employees
1
Country
Sweden
ISIN
SE0014555066

Listings

ST
SE
LIDDS-BTA.ST

0 Comments

Share your thoughts

FAQ

What is Lidds AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Stockholm Exchange exchange Lidds AB stocks are traded under the ticker LIDDS-BTA.ST.
How many employees does Lidds AB have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is Lidds AB located?▼
Lidds AB operates in the Health & Wellness sector.
When did Lidds AB complete a stock split?▼
Lidds AB has not had any recent stock splits.
Where is Lidds AB headquartered?▼
Lidds AB is headquartered in Stockholm, Sweden.